NEW YORK (Reuters) – Gilead Sciences Inc (O:) said on Sunday it was temporarily putting emergency access to its experimental coronavirus drug remdesivir on hold due to overwhelming demand and that it wanted most people receiving the drug to participate in a clinical trial to prove if it is safe and effective.
The drugmaker said in a statement there had been an exponential increase in so-called compassionate-use requests for the drug. It was shifting from a system of individual compassionate-use requests to expanded access programs, which it expects will start in a similar time frame that new requests for compassionate use would have been processed.
Gilead said it would make exceptions for pregnant women and children under 18 with severe COVID-19, the respiratory disease caused by the coronavirus.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.